A draft bill from the Senate Health, Education, Labor and Pensions Committee would define the respective roles of state authorities and the FDA in the oversight of pharmaceutical compounding companies. Under the proposed legislation, traditional drug compounding to fill patient prescriptions would continue to be the responsibility of states. The FDA, however, would oversee compounding manufacturers that make sterile products without prescriptions and transport them across state lines.

Related Summaries